Onconetix 2025 10-K: Revenue $0.82M, EPS $(16.56)

Onconetix reported 2025 revenue of $0.82 million and a net loss per share of $(16.56) as disclosed in its Form 10-K, reflecting a steep revenue decline tied to the completion of prior development services and a company-wide shift to commercialization. Despite lower top-line results, the company posted improvements in operating loss and net loss versus 2024 driven by cost reductions and strategic refocusing. The filing outlines a move to commercialize Proclarix while streamlining operations to conserve resources. Financial Highlights Revenue: $0.82 million, decreased $1.71 million (−67.7%) versus 2024 (Part II, Item 8 and MD&A).Gross Profit: $0.63 million, down $0.42 million (−40.0%) versus 2024 (Part II, Item 8 and MD&A).Operating Income (Loss): $(17.86) million, an improvement of $38.63 million (−68.4%) versus 2024 (Part II, Item 8).Net Income (Net loss): $(14.03) million, improved $44.66 million (−76.1%) versus 2024 (Part II, Item 8).Net Income Per Share: $(16.56) (basic and diluted); weighted average shares 937,690 (Part II, Item 8). Business Highlights Commercial Focus Shift: The company transitioned to a commercial stage, halting its vaccine programs to concentrate resources on commercializing Proclarix.Revenue Trend: The decline in 2025 revenue was driven by the completion of 2024 development services; product sales remained steady at approximately $0.2 million.Market Access & Partnerships: Proclarix is CE-marked in the EU; the company holds an exclusive LabCorp U.S. license for an LDT pathway and is collaborating on a PRIME validation study.Operational Streamlining: Management implemented cost reductions including headcount reductions, terminated ENTADFI commercialization, and recorded related asset impairments to conserve resources.Commercial Readiness: Proclarix is designed for easy laboratory integration (ELISA) targeting PSA 'grey zone' patients with rapid risk scoring to support diagnostic decision-making.Original SEC Filing: Onconetix, Inc. [ ONCO ] - 10-K - Mar. 13, 2026DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.